DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Access and Reimbursement

Our Access & Reimbursement Portfolio brings DRG market access and therapy experts together with national and regional payers, to uncover key indication- and country-specific drivers of reimbursement. Our physician and payer research uncovers how reimbursement constraints play out in the real world, and how industry can engage.

 

What is Access & Reimbursement

ppr

Prescribers share prescribing drivers and constraints, as well as perceptions of value. Key reimbursement stakeholders share preferences and considerations. DRG analysts deliver brand-level insights:

  • The impact of payer policy on prescribing
  • Market access success and stumbles of key brands in respective markets
  • Case studies: best practices vs. lessons learned
  • Analysis of key market access challenges for currently approved and emerging therapies
  • Actionable recommendations to drive optimal access

 

Talk to us

 

Market Access Considerations for COPD and Asthma

How will the behavior of payers play a role in shaping the market access land-scape for both COPD and asthma in the United States and EU5. DRG's Market Access experts share their thoughts.

Reports Related to our Respiratory White Paper


COPD | Access & Reimbursement | US
COPD | Access & Reimbursement | EU5

Asthma | Access & Reimbursement | US
Asthma | Access & Reimbursement | EU5